Company Presentation
AB2 Bio Ltd.
| Country: | Switzerland |
| Category: | Emerging Biotech Company Presentation |
| Room: | Singapore |
| Date: | 02.05.2022 |
| Time: | 17:00 – 17:15 |
| Website: | www.ab2bio.com |
| Speaker: | Djordje Filipovic, Ph.D. |
Company profile
Phase 3 stage Company developing therapies for the treatment of IL-18 mediated systemic hyper-inflammatory disorders with high unmet medical need. Tadekinig alfa, the recombinant version of physiological human IL-18 Binding Protein, will treat the underlaying disease mechanisms by restoring IL-18 homeostasis. First BLA submission planned for 2023 in monogenic primary HLH. PoC and PoC ready in Still’s Disease, HSCT and MAS-like syndromes / CRS associated with CAR-T.
